MétaCan
Menu
Back to cohort
Record W4411589867 · doi:10.1016/j.josat.2025.209743

The effect of craving on retention and treatment switching under buprenorphine-naloxone and methadone models of care for non-heroin opioid use disorder: Exploratory analyses from a pragmatic, randomized controlled trial

2025· article· en· W4411589867 on OpenAlexafffund
Christina McAnulty, Gabriel Bastien, Anita Abboud, Arash Bahremand, Omar Ledjiar, M. Eugenia Socías, Bernard Le Foll, Louis-Christophe Juteau, Didier Jutras‐Aswad

Bibliographic record

VenueJournal of Substance Use and Addiction Treatment · 2025
Typearticle
Languageen
FieldMedicine
TopicOpioid Use Disorder Treatment
Canadian institutionsCegep Edouard MontpetitBritish Columbia Centre on Substance UseCentre for Addiction and Mental HealthCentre Hospitalier Universitaire Sainte-JustineCentre Hospitalier de l’Université de Montréal
FundersCanadian Institutes of Health ResearchUniversity of TorontoDepartment of Psychiatry, University of TorontoPfizerCentre for Addiction and Mental Health FoundationBioprojetCentre for Addiction and Mental HealthUniversal
KeywordsBuprenorphineMethadoneHeroinCraving(+)-NaloxoneOpioid use disorderRandomized controlled trialOpioidPsychologyMedicineNarcotic antagonistsPsychiatryAnesthesiaClinical psychologyPsychotherapistAddictionDrugInternal medicine

Abstract

fetched live from OpenAlex

INTRODUCTION: Though opioid agonist therapies are the mainstay of treatment for opioid use disorder, treatment retention remains suboptimal. Improved prediction of who will remain in treatment could lead to improved treatment outcomes. Whether craving predicts reduced retention in treatment remains debated. We performed analyses to determine whether craving predicted treatment attrition or treatment switching in people with non-heroin opioid use disorder initiating opioid agonist therapy. METHODS: Our data came from the OPTIMA trial - a pan-Canadian, pragmatic, open-label, randomized controlled trial that compared a flexible, early take-home buprenorphine/naloxone model of care (n = 137) to standard treatment with methadone (n = 132) for non-heroin opioid use disorder over a period of 24 weeks. We performed Cox proportional hazards regression to conduct survival analyses of time (days) to treatment attrition, and time to switch to another treatment, with craving as a time-varying covariate, controlling for assigned treatment group, lifetime history of heroin use and province. Craving was measured at baseline, week 2, 6, 10, 14, 18, 22 using the Brief Substance Craving Scale. RESULTS: We found that craving predicted both treatment drop out and treatment switching. A 1-point increase in craving was associated with a 15.3 % increase of risk of dropping out of the study (HR = 1.153, 95 % CI = 1.065 to 1.248, p < 0.001) and with a 11.5 % increase of risk of switching treatment (HR = 1.115, 95 % CI = 1.016 to 1.225, p = 0.022). CONCLUSIONS: Craving predicted both treatment attrition and treatment switching in people receiving buprenorphine/naloxone or methadone models of care for non-heroin opioid use disorder. These findings highlight the importance of targeting and better addressing craving during treatment with opioid agonist therapies.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.014
metaresearch head score (Gemma)0.026
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.014
Threshold uncertainty score0.076

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0140.026
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0070.012
Bibliometrics0.0010.001
Science and technology studies0.0010.003
Scholarly communication0.0020.003
Open science0.0020.001
Research integrity0.0030.005
Insufficient payload (model declined to judge)0.0060.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.026
GPT teacher head0.303
Teacher spread0.276 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes2
Has abstractno

Explore more

Same venueJournal of Substance Use and Addiction TreatmentSame topicOpioid Use Disorder TreatmentFrench-language works237,207